Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1709-1718

  Vehreschild, J J ^a   Bohme A ^b   Cornely, O A ^a,c   Kahl, C ^d   Karthaus, M ^e   Kreuzer, K A ^a   Maschmeyer, G ^f   Mousset, S ^g   Ossendorf, V ^a   Penack, O ^h   Vehreschild, M J G T ^a   Bohlius, J ⁱ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Onkologikum Frankfurt am Museumsufer   (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Clinic for Haematology and Oncology Klinikum Magdeburg gGmbH   (Switzerland)

^e Haematology Oncology and Palliative Care Hospital Neuperlach and Hospital Harlaching   (Switzerland)

^f Department of Haematology Oncology and Palliative Care Klinikum Ernst von Bergmann   (Switzerland)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; Evidence based guideline; Febrile neutropenia; G CSF; Infection; Supportive care

Indexed keywords

COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINCRISTINE; XM 02; BIOSIMILAR AGENT; PLATINUM DERIVATIVE; RITUXIMAB; GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL DERIVATIVE; PEGFILGRASTIM; PEGYLATED GRANULOCYTE COLONY-STIMULATING FACTOR, HUMAN; RECOMBINANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTION; INFECTION PREVENTION; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; CANCER PATIENT; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; INFECTION RATE; INFECTION RISK; INFECTIOUS COMPLICATION; LUNG CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEPTICEMIA; ANTIBIOTIC PROPHYLAXIS; COMMUNICABLE DISEASES; INFECTION CONTROL; MICROBIOLOGY; NEOPLASMS; PROCEDURES;

ADULT; ANTIBIOTIC PROPHYLAXIS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; EVIDENCE-BASED MEDICINE; FEBRILE NEUTROPENIA; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84906852006     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu035     Document Type: Review

References (107)

1. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 00: 328-340.
2. Bodey GP. Infection in cancer-patients-a continuing association. Am J Med 1986; 81: 11-26.
3. Weissinger F, Auner HW, Bertz H et al. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012; 91: 1161-1174.
4. Talcott JA, Siegel RD, Finberg R et al. Risk assessment in cancer-patients with fever and neutropenia-a prospective, 2-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
5. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
6. Lyman GH, Dale DC, Culakova E et al. The impact of the granulocyte colonystimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24: 2475-2484.
7. Snider S. G-CSF Approved to Protect Cancer Chemo Patients P91-6 Food and Drug Administration. 1991.
8. de Arriba F, Lozano ML, Ortuno F et al. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol 1997; 96: 418-420.
9. Orciuolo E, Buda G, Marturano E et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res 2011; 35: 899-903.
10. Mattii L, Battolla B, Azzara A et al. Glycosylation interference on RhoA activation: focus on G-CSF. Leuk Res 2011; 35: 265-267.
11. Sourgens H, Lefrere F. A systematic review of available clinical evidence- filgrastim compared with lenograstim. Int J Clin Pharmacol Ther 2011; 49: 510-518.
12. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001; 7: 2085-2090.
13. Molineux G, Kinstler O, Briddell B et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
14. Johnston E, Crawford J, Blackwell S et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
15. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
16. Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
17. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
18. Vose JM, Crump M, Lazarus H et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
19. Grigg A, Solal-Celigny P, Hoskin P et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503-1508.
20. Sierra J, Szer J, Kassis J et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-tointermediate risk acute myeloid leukemia: results from a randomized, doubleblind, phase 2 trial. BMC Cancer 2008; 8: 195.
21. Del Giglio A, Eniu A, Ganea-Motan D et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008; 8: 332.
22. Engert A, Griskevicius L, Zyuzgin Y et al. XM02, the first granulocyte colonystimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009; 50: 374-379.
23. Gatzemeier U, Ciuleanu T, Dediu M et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009; 4: 736-740.
24. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
25. Ozer H. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. Curr Opin Hematol 1996; 3: 3-10.
26. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558-3585.
27. Smith TJ, Khatcheresian J, Lyman GH et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 1-19.
28. Timmer-Bonte JN, de Boo TM, Smit HJ et al. Prevention of chemotherapyinduced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-7984.
29. Vogel CL, Wojtukiewicz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178-1184.
30. National Comprehensive Cancer Network, Critical Guidelines in Oncology. Myeloid Growth Factors in Cancer Treatment. [v.2.2005]. 2005.
31. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
32. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
33. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. 2009.
34. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2012. 2012.
35. Lyman GH, Kuderer NM, Crawford J et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917-1927.
36. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854.
37. Bui BN, Chevallier B, Chevreau C et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995; 13: 2629-2636.
38. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer. N Engl J Med 1991; 325: 164-170.
39. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-324.
40. Fukuoka M, Masuda N, Negoro S et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75: 306-309.
41. Gatzemeier U, Kleisbauer JP, Drings P et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000; 23: 393-400.
42. Hidalgo M, Mendiola C, Lopez-Vega JM et al. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer 1998; 83: 719-725.
43. Papaldo P, Lopez M, Cortesi E et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 2003; 21: 3462-3468.
44. Osby E, Hagberg H, Kvaloy S et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840-3848.
45. Pettengell R, Gurney H, Radford JA et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-1436.
46. Zinzani PL, Pavone E, Storti S et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-3979.
47. Dunlop DJ, Eatock MM, Paul J et al. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998; 10: 107-114.
48. Aviles A, Diaz-Maqueo JC, Talavera A et al. Effect of granulocyte colonystimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leuk Lymphoma 1994; 15: 153-157.
49. Aglietta M, Montemurro F, Fagioli F et al. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer 2000; 88: 454-460.
50. Ossenkoppele GJ, van der HB, Verhoef GE et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia 1999; 13: 1207-1213.
51. Zwierzina H, Suciu S, Loeffler-Ragg J et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005; 19: 1929-1933.
52. Holowiecki J, Giebel S, Krzemien S et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma 2002; 43: 315-325.
53. Geissler K, Koller E, Hubmann E et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia-a randomized phase-III study. Blood 1997; 90: 590-596.
54. Thomas X, Boiron JM, Huguet F et al. Efficacy of granulocyte and granulocytemacrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J 2004; 5: 384-394.
55. Heil G, Hoelzer D, Sanz MA et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710-4718.
56. Ohno R, Naoe T, Kanamaru A et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086-2092.
57. Lowenberg B, van Putten W, Theobald M et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
58. Usuki K, Urabe A, Masaoka T et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116: 103-112.
59. Harousseau JL, Witz B, Lioure B et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-787.
60. Bradstock K, Matthews J, Young G et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001; 15: 1331-1338.
61. Bernasconi C, Alessandrino EP, Bernasconi P et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102: 678-683.
62. Godwin JE, Kopecky KJ, Head DR et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607-3615.
63. Dombret H, Chastang C, Fenaux P et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678-1683.
64. Amadori S, Suciu S, Jehn U et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
65. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colonystimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671-1677.
66. Witz F, Sadoun A, Perrin M-C et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998; 91: 2722-2730.
67. Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
68. Lowenberg B, Suciu S, Archimbaud E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952-2961.
69. Lofgren C, Paul C, Astrom M et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 2004; 124: 474-480.
70. Hecht JR, Pillai M, Gollard R et al. A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010; 9: 95-101.
71. Soda H, Oka M, Fukuda M et al. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 1996; 38: 9-12.
72. Bassan R, Lerede T, Di Bona E et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma 1997; 26: 153-161.
73. Beveridge RA, Miller JA, Kales AN et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998; 16: 366-373.
74. Kaku K, Takahashi M, Moriyama Y et al. Recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial. Leuk Lymphoma 1993; 11: 229-238.
75. Loibl S, Mueller V, von Minckwitz G et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 2011; 19: 1789-1795.
76. Balducci L, Al-Halawani H, Charu V et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12: 1416-1424.
77. Zwick C, Hartmann F, Zeynalova S et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 2011; 22: 1872-1877.
78. Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
79. Fossa SD, Kaye SB, Mead GM et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16: 716-724.
80. Masuda N, Fukuoka M, Furuse K. CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology 1992; 49(Suppl 1): 19-24.
81. Negoro S, Masuda N, Furuse K et al. Dose-intensive chemotherapy in extensivestage small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40(Suppl): S70-S73.
82. Papaldo P, Lopez M, Marolla P et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 6908-6918.
83. Trillet-Lenoir V, Green JA, Manegold C et al. Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term followup. Eur J Cancer 1995; 31A: 2115-2116.
84. Woll PJ, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-659.
85. Itamochi H, Irie T, Okada M et al. An optimal regimen of G-CSF (granulocyte colony-stimulating factor) treatment after anticancer chemotherapy for patients with gynecologic malignancy. J Jpn Soc Cancer Ther 1995; 30: 776-780.
86. Katakami N, Hasegawa T, Umeda B et al. Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer-multi-center randomized crossover study. Jpn J Thorac Dis 1996; 34: 520-528.
87. Gisselbrecht C, Haioun C, Lepage E et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997; 25: 289-300.
88. Fridrik MA, Greil R, Hausmaninger H et al. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVPDexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Ann Hematol 1997; 75: 135-140.
89. Doorduijn JK, van der Holt B, van ImhoffGW et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non- Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-3050.
90. Bohlius J, Reiser M, Schwarzer G et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004; CD003189.
91. Larson RA, Dodge RK, Linker CA et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556-1564.
92. Ottmann OG, Hoelzer D, Gracien E et al. Concomitant granulocyte colonystimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86: 444-450.
93. Hofmann WK, Seipelt G, Langenhan S et al. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol 2002; 81: 570-574.
94. von Lilienfeld-Toal M, Hahn-Ast C, Kirchner H et al. A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy. Haematologica 2007; 92: 1719-1720.
95. Wheatley K, Goldstone AH, Littlewood T et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146: 54-63.
96. Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005; 23: 2988-2995.
97. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
98. Morstyn G, Souza LM, Keech J et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cyto-toxic chemotherapy. Lancet 1988; 1: 667-672.
99. Yoshida T, Nakamura S, Ohtake S et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 1990; 66: 1904-1909.
100. Hovgaard DJ, Nissen NI. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. J Clin Oncol 1992; 10: 390-397.
101. Alvarado Ibarra ML, Borbolla Escoboza JR, Lopez-Hernandez MA et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Rev Invest Clin 1999; 51: 77-80.
102. Beveridge RA, Miller JA, Kales AN et al. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteriaderived RhuGM-CSF) in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer 1997; 5: 289-298.
103. Aarts MJ, Grutters JP, Peters FP et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 2013; 31: 4283-4289.
104. Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
105. Patt DA, Duan Z, Fang S et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007; 25: 3871-3876.
106. Renner P, Milazzo S, Liu JP et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 2012; 10: CD007913.
107. Chan KK, Siu E, Krahn MD et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol 2012; 30: 1064-1071.